ADCs have the potential to revolutionize the treatment of several cancers, but also autoimmune and infectious diseases, making them a significant
and promising class of therapies. Consequently, the US and EU approved
33 antibody therapeutics between 2016 and 2020, with most targeting
various tumors, while China only approved 10 during the same period.
In 2022, the number of ADCs approved in both regions was nearly the same as between 2016 and 2020, indicating the high growth potential of this form of therapy (Fig 1). However, in 2022 percentagewise the development focus of anti-cancer antibody therapeutics has shifted towards China, with around
67% of approvals for this disease in the region (Fig 2). |
|
